BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2004

View Archived Issues

Preclinical antitumor activity of the novel Hsp90 inhibitor IPI-504

Read More

AV-201 enters phase I/II trial for Parkinson's disease

Read More

NIAID to test preventive SARS vaccine

Read More

Solvay seeks to acquire Neopharma

Read More

Accera establishes advisory boards to guide development efforts

Read More

Enrollment on track in ASSIST-2 study of Telcyta

Read More

NIAID approval for advanced preclinical testing of Mymetics' HIV vaccine

Read More

New liver safety information for Strattera

Read More

Proteome Systems to acquire Eukarion

Read More

MorphoSys and Schering AG extend collaboration

Read More

BMS and Gilead to develop fixed combination HIV medication

Read More

Allon files IND for phase I trial of AL-108 for Alzheimer's

Read More

Genaissance identifies markers implicated in clozapine-induced agranulocytosis

Read More

Cryptome to apply drug discovery platform to neuroinflammatory diseases

Read More

FTC does not oppose potential collaboration between Basilea and J&J

Read More

Three patents covering 5-HT4 receptor modulators filed by Dainippon

Read More

Ono discloses chemokine receptor ligands

Read More

New patent application covers antidiabetic agents

Read More

Two series of p38 MAP kinase inhibitors described in patent literature

Read More

AxyS (Celera Genomics) researchers prepare and test HDAC inhibitors for leukemia

Read More

Positive E.U. opinion for Pegasys combination therapy in HIV-HCV patients

Read More

Broad-spectrum caspase inhibitor blocks apoptosis in rodent model

Read More

Novel inhibitor of ABL tyrosine kinase more effective than imatinib in vivo

Read More

Remicade receives FDA approval for ankylosing spondylitis

Read More

Novel lipoxin analogue from Berlex promising for the treatment of IBD

Read More

Simvastatin plus chemotherapy induce antitumor response in end-stage myeloma or lymphoma

Read More

Cognitive improvements found with epoetin alfa in anemic patients with hematologic malignancies

Read More

FavId vaccine improves antitumor efficacy of rituximab in follicular lymphoma

Read More

Levoamphetamine reported to improve memory and cognition

Read More

Update on the efficacy of pregabalin in patients with partial seizures

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing